Urology Times 50 Innovations Series: BCG therapy for bladder cancer
"It is clearly the standard and it's the treatment of choice. When you have that, and it's very good, it's evidenced by the fact that none of the agents are compared against BCG because it sets such a high standard of effectiveness," says Sam S. Chang, MD, MBA.
EP: 1.Urology Times 50 Innovations Series: PSA testing
EP: 2.Urology Times 50 Innovations Series: Testosterone therapy
EP: 3.Urology Times 50 Innovations Series: Stem cell–derived therapy for stress urinary incontinence
EP: 4.Urology Times 50 Innovations Series: Tissue engineering and regenerative medicine
EP: 5.50th Anniversary Innovation Celebration: The midurethral sling for stress urinary incontinence
EP: 6.Urology Times 50 Innovations Series: Genetic testing for prostate cancer
EP: 7.Urology Times 50 Innovations Series: Onabotulinumtoxin A for overactive bladder
EP: 8.Urology Times 50 Innovations Series: Clean intermittent catheterization
EP: 9.Urology Times 50 Innovations Series: Viagra for treatment of erectile dysfunction
EP: 10.Urology Times 50 Innovations Series: Active surveillance for prostate cancer
EP: 11.Urology Times 50 Innovations Series: BCG therapy for bladder cancer
EP: 12.Urology Times 50 Innovations Series: Extracorporeal shock wave lithotripsy for stones
EP: 13.Urology Times 50 Innovations Series: Treatment of female hypoactive sexual desire disorder
EP: 14.Urology Times 50 Innovations Series: Cryotherapy for kidney and prostate cancer
EP: 15.Urology Times 50 Innovations Series: Intralesional therapies for Peyronie's disease
EP: 16.Urology Times 50 Innovations Series: Radiation therapy for prostate cancer
EP: 17.Urology Times 50 Innovations Series: β3 agonists for overactive bladder
EP: 18.Urology Times 50 Innovations Series: Microsurgical testicular sperm extraction
EP: 19.Urology Times 50 Innovations Series: Anatomic radical prostatectomy
EP: 20.Urology Times 50 Innovations Series: Dr. Kelvin Moses on sipuleucel-T for mCRPC
EP: 21.Urology Times 50 Innovations Series: Dr. Jennifer Linehan on HIFU for prostate cancer
EP: 22.Urology Times 50 Innovations Series: Transrectal ultrasound-based prostate biopsy
EP: 23.Urology Times 50 Innovations Series: Neobladder reconstruction
EP: 24.Urology Times 50 Innovations Series: Multichannel urodynamics
EP: 25.Urology Times 50 Innovations Series: Treatments for male infertility
EP: 26.Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancer
EP: 27.Urology Times 50 Innovations Series: Blue light cystoscopy for the detection of bladder cancer
EP: 28.Urology Times 50 Innovations Series: LHRH analogues in prostate cancer
EP: 29.Urology Times 50 Innovations Series: Advancements in vesicovaginal fistula repair
EP: 30.Urology Times 50 Innovations Series: Artificial urinary sphincter
EP: 31.Urology Times 50 Innovations Series: PSMA-PET imaging in prostate cancer
EP: 32.Urology Times 50 Innovations Series: Sacral neuromodulation
EP: 33.Urology Times 50 Innovations Series: Penile prostheses
EP: 34.Urology Times 50 Innovations Series: Multiparametric MRI in prostate cancer
EP: 35.Urology Times 50 Innovations Series: Intracavernosal injections for erectile dysfunction
EP: 36.Urology Times 50 Innovations Series: Bulking injections for stress urinary incontinence
EP: 37.Dr. Gill explains the importance of BPH treatment innovations to urology
EP: 38.50th Anniversary Innovation Celebration: Buccal mucosa grafts for urethral strictures
As part of the Urology Times' 50th Anniversary Innovation Celebration, Sam S. Chang, MD, MBA, discusses the many ways in which BCG has improved the management of patients with bladder cancer. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
